In brief: Ventracor granted patents; Pentrys trial completes recruiting
Friday, 18 March, 2005
The US Patent and Trademark Office has granted Ventracor (ASX:VCR) and the company's research partners at the University of Technology Sydney a patent over the control system used in its VentrAssist heart device.
US patent number 6,866, 625 covers the electronic controls by which VentrAssist monitors blood flow and adapts the output of the impeller accordingly.
In April, Ventracor is due to be granted a new European patent, number 1019116, relating to the mechanical aspects of VentrAssist.
Ventracor has 20 patent families which encompass over a hundred granted international patents relating to the suspended dynamic impeller in the company's VentrAssist device. The company also has over 30 patents pending global jurisdictions, primarily Europe and the US.
Recruiting for Phase IIb Pentrys trial complete
Sydney oncology company AustCancer (ASX:ACU, OTCBB:ACUJY) announced today it has completed recruiting for its Phase IIb clinical trial of its Pentrys peptide vaccine in 40 male patients with hormone-refractory prostate cancer.
The multi-centre trial is being conducted by Cancer Trials Australia at Melbourne's Austin Health, Royal Melbourne Hospital and the Peter MacCallum Cancer Centre. It is designed to confirm the vaccine's safety and clinical efficacy.
The new vaccine is designed to elicit an antibody reaction to mutant peptides of the tumour-suppressor protein P53, which is abnormally displayed on the surface of tumour cells in about 50 per cent of all cancers.
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
Stem cell experiments conducted in space
Scientists are one step closer to manufacturing stem cells in space — which could speed up...
